Chimeric antigen receptor-modified autologous T cell injection targeting CD19 (Bio-gene)

靶向CD19的嵌合抗原受体修饰的自体T细胞（广州百暨基因科技）

Report date: 2024/06/27 20:00:09

Base Information

Drug NameChimeric antigen receptor-modified autologous T cell injection targeting CD19 (Bio-gene)
Drug Alias NameBG-T19BG-19BG-19C
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Bio-Gene Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Bio-Gene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A